Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome by de Matos Soeiro, Alexandre et al.
Mortality reduction with use of oral beta-blockers in
patients with acute coronary syndrome
Alexandre de Matos Soeiro,I,* Pedro Gabriel Melo de Barros e Silva,II Eduardo Alberto de Castro Roque,III
Aline Siqueira Bossa,I Cindel Nogueira Zullino,I Sheila Aparecida Simo˜es,II Mariana Yumi Okada,II
Tatiana de Carvalho Andreucci Torres Leal,I Maria Carolina Feres de Almeida Soeiro,I
Carlos V. Serrano Jr.,I Mu´cio Tavares Oliveira Jr.I
I Faculdade de Medicina da Universidade de Sa˜o Paulo, Instituto do Corac¸a˜o (InCor), Unidade de Emergeˆncia, Sa˜o Paulo/SP, Brazil. IIHospital TotalCor,
Sa˜o Paulo/SP, Brazil. IIIHospital Metropolitano, Serra/ES, Brazil.
OBJECTIVES: Recent studies have revealed a relationship between beta-blocker use and worse prognosis in
acute coronary syndrome, mainly due to a higher incidence of cardiogenic shock. However, the relevance of this
relationship in the reperfusion era is unknown. The aim of this study was to analyze the outcomes of patients
with acute coronary syndrome that started oral beta-blockers within the first 24 hours of hospital admission
(group I) compared to patients who did not use oral beta-blockers in this timeframe (group II).
METHODS: This was an observational, retrospective and multicentric study with 2,553 patients (2,212 in group I
and 341 in group II). Data regarding demographic characteristics, coronary treatment and medication use in the
hospital were obtained. The primary endpoint was in-hospital all-cause mortality. The groups were compared
by ANOVA and the chi-square test. Multivariate analysis was conducted by logistic regression and results were
considered significant when po0.05.
RESULTS: Significant differences were observed between the groups in the use of angiotensin-converting
enzyme inhibitors, enoxaparin, and statins; creatinine levels; ejection fraction; tabagism; age; and previous
coronary artery bypass graft. Significant differences were also observed between the groups in mortality (2.67%
vs 9.09%, OR=0.35, p=0.02) and major adverse cardiovascular events (11% vs 29.5%, OR=4.55, p=0.02).
CONCLUSIONS: Patients with acute coronary syndrome who underwent early intervention with oral beta-
blockers during the first 24 hours of hospital admission had a lower in-hospital death rate and experienced
fewer major adverse cardiovascular events with no increase in cardiogenic shock or sustained ventricular
arrhythmias compared to patients who did not receive oral beta-blockers within this timeframe.
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’ INTRODUCTION
Beta-blockers are the main drug treatment used for
patients with acute myocardial infarction (AMI). American
Heart Association (ACCF/AHA) guidelines provide a class I
recommendation for oral beta-blockers within the first
24 hours of symptom onset and a class IIa indication for
intravenous beta-blockers for patients who are hypertensive
or have ongoing ischemia (1,2). Not surprisingly, healthcare
organizations have adopted the use of beta-blockers at
discharge following myocardial infarction as a quality indi-
cator (3-6).
All guidelines that support the use of beta-blockers in AMI
predate reperfusion and contemporary medical therapy with
statins and antiplatelet agents (3). Recent data have called
into question the role of beta-blockers in AMI, particularly
regarding the type, dosage and duration of treatment for
patients whose post-AMI course is without arrhythmia, heart
failure or recurrent ischemia. In the pre-reperfusion era, reduc-
tions in mortality have been reported with beta-blocker use,
but the role of this treatment in the reperfusion era is not
clear. Notably, in the reperfusion era, only reductions in
myocardial infarction and angina have been observed,
whereas increases in heart failure and cardiogenic shock
have occurred (3,7-10).
Based on the above, the objective of this study was to
analyze the short-term outcomes of patients with acute
coronary syndrome (ACS) who started oral beta-blockersDOI: 10.6061/clinics/2016(11)03
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during the first 24 hours of hospital admission and to
compare these outcomes to those of patients who did not use
oral beta-blockers within this timeframe.
’ MATERIALS AND METHODS
Study population
This study had an observational, multicentric and ret-
rospective design. Databank analysis was performed for
2,553 patients with ACS (ST elevation myocardial infarc-
tion [STEMI] and non-ST elevation myocardial infarction
[NSTEMI]) who were treated in a tertiary health center
between May 2010 and May 2014. The patients were divided
into the following two groups: patients who started oral
beta-blockers within the first 24 hours of admission (group I,
n=2,212) and patients who did not take oral beta-blockers
during this timeframe (group II, n=341). Patients who were
treated with intravenous beta-blockers or who presented
with cardiogenic shock or bradycardia were excluded.
Patients were diagnosed and treated according to AHA/
ESC Task Force guidelines (1,2). All patients underwent
percutaneous coronary intervention less than 24 hours after
the onset of ACS. The following beta-blockers were used:
propranolol, atenolol, carvedilol and metoprolol.
The primary outcome was in-hospital all-cause mortality.
The secondary outcome was major adverse cardiac events
(MACE), including all causes of death, non-fatal angina or
AMI/target vessel revascularization, cardiogenic shock,
bleeding (major and minor), sustained ventricular arrhyth-
mia and stroke.
The study was approved by the ethics and research
committee, and informed consent was obtained from all
patients or their family members.
Analytical methods
The following data were obtained: age, sex, diabetes,
systemic arterial hypertension, tabagism, dyslipidemia,
familial history of premature coronary artery disease, heart
failure, previous coronary artery disease, previous stroke,
hematocrit, creatinine, troponin, systolic arterial pressure, left
ventricle ejection fraction and medications used within the
first 24 hours of admission (Table 1).
Blood was sampled immediately after admission and prior
to administration of medications (baseline) and then daily
according to institutional protocols. Cardiac markers, such as
troponin-I, were measured using standard clinical chemistry.
The laboratory upper limits of normal were 0.04 ng/ml (99th
percentile) for troponin-I, which was measured using an
Elecsys 2010 (Siemens Healthcare Diagnostics Inc., United
States of America) 4th generation immunoassay.
Major bleeding was defined using BARC (11) scores: types 3
and 5 indicated major bleeding, while types 1 and 2 indicated
minor bleeding. Post-operative bleeding was not considered.
Sustained ventricular arrhythmia was defined as sustained
ventricular tachycardia with or without pulse and ventri-
cular fibrillation.
Statistical analysis
The collected data were submitted to descriptive analysis,
including determination of the median and the minimum
and maximum values. Comparisons between groups were
made by ANOVA and the chi-square test. If the Kolmogorov-
Smirnov test confirmed a normal distribution, then contin-
uous variables were summarized using the mean±standard
deviation and were compared using Student’s t-test for
independent samples. The Mann-Whitney U test was used to
compare continuous variables if they were not normally
distributed.
Multivariate analysis was performed using logistic regres-
sion, and the results were considered significant when
po0.05. The variables included all baseline characteristics
shown in Table 1.
All statistical procedures were performed using the
statistical software package SPSS, v10.0.
’ RESULTS
The median age was 62 years, and approximately 40.5%
of the cohort was male. The most prevalent risk factor was
hypertension (76%), followed by dyslipidemia (48%). In
total, 25% of the patients in group I had STEMI compared to
29% of the patients in group II. Approximately 40% of the
patients in group I underwent percutaneous coronary inter-
vention compared with 29% of the patients in group II.
Coronary artery bypass surgery was performed on 17% of
the patients in group I and 8% of the patients in group II.
We observed significant differences in the prevalence
of the use of angiotensin-converting enzyme inhibitors
(87.27% vs 51.32%, po0.0001), enoxaparin (77.1% vs 72.2%,
p40.0001), and statins (95.1% vs 75.2%, po0.0001), as well as
in creatinine (1.47 mg/dL vs 2.09 mg/dL, p=0.03), ejection
fraction (49.77% vs 43.14%, po0.0001), tabagism (30.41% vs
38.71%, p=0.001), age (59 vs 70 years, p=0.03) and previous
coronary artery bypass graft (14% vs 11%, p=0.003) between
groups I and II (Table 1).
Multivariate analysis results are presented in Table 2,
which describes the differences between groups I and II
regarding the incidences of death (2.67% vs 9.09%, OR=0.35,
p=0.02) and MACE (11% vs 29.5%, OR=4.55, p=0.02). There
Table 1 - Baseline characteristics of patients with or without the
use of beta-blockers within the first 24 hours of hospital
admission.
Beta-blocker + Beta-blocker - p
Age (median) 59 70 0.03
Male (%) 63% 59% 0.13
Diabetes mellitus (%) 39% 33% 0.68
Hypertension (%) 77% 71% 0.12
Tabagism (%) 30% 39% 0.001
FH of CAD (%) 13% 11% 0.47
Dyslipidemia (%) 49% 43% 0.12
Heart failure (%) 9% 4% 0.105
Previous stroke (%) 5% 5% 0.51
Previous AMI (%) 33% 31% 0.15
Previous CABG (%) 14% 11% 0.003
Previous PCI (%) 19% 21% 0.06
Ht (%) (median) 41.2 41.8 0.18
Cr (mg/dL) (median) 1.47 2.09 0.03
Troponin (ng/dL) (higher) 2.46 3.12 0.7
SAP (mmHg) (median) 133.7 127 0.29
EF (%) (median) 49.8 43.1 o 0.0001
AAS (%) 99% 95% 0.1
Enoxaparin (%) 77% 72% o0.0001
ACE inhibitor (%) 87% 51% o0.0001
Statin (%) 95% 75% o0.0001
Legend: FH=familial history; CAD=coronary artery disease; AMI=acute
myocardial infarction; CABG=coronary artery bypass grafting;
PCI=percutaneous coronary intervention; SAP=systolic arterial pressure;
Ht=hematocrit; Cr=creatinine; EF=ejection fraction; ACE=angiotensin-
converting enzyme.
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were no differences in the incidences of cardiogenic shock
(3.5% vs 9.4%, OR=0.57, p=0.1) or sustained ventricular
arrhythmia (0.7% vs 3.8%, OR=1.24, p=0.23) between the two
groups (Table 2).
’ DISCUSSION
In this study, we acquired results that differ from recently
reported data. We found that the use of beta-blockers within
the first 24 hours of ACS onset decreased in-hospital
mortality and MACE. In contrast with other findings, the
use of oral beta-blockers tended to reduce the incidence of
cardiogenic shock.
The issue of whether to use beta-blockers in AMI has
been discussed for more than 30 years. In 1981, Hjalmarson
et al. (12) compared the effect of metoprolol on mortality in
1,395 patients with AMI; the metoprolol treatment began as
soon after admission as possible and continued for 90 days.
The mortality rates were 8.9% in the placebo group and 5.7% in
the metoprolol group, resulting in an overall mortality reduc-
tion of 36% (po0.03) (12). Similar results were observed in our
study only when oral beta-blockers were administered.
Similarly, in the CAPRICORN trial, 1,959 patients with
AMI and a left-ventricular ejection fraction of less than or
equal to 40% were randomly assigned to receive oral carvedilol
or placebo with follow-up until the requisite number of
primary endpoints had occurred. Although there was no dif-
ference between the groups regarding the primary endpoint
(all-cause mortality or hospital admission for cardiovascular
problems), all-cause mortality was lower in the carvedilol
group than the placebo group (12% vs 15%, 0.77 [0.60–0.98],
p=0.03). In-hospital differences were not analyzed, and only
46% of the patients underwent percutaneous coronary inter-
vention (PCI) or thrombolysis (13). These results are also
concordant with our study, although we did not follow patients
after discharge, and our study included patients with an
ejection fraction greater than 40%.
A study published in 2014 evaluated 26,793 patients after
undergoing a first cardiovascular event (ACS or coronary revas-
cularization). Over an average of 3.7 years of follow-up, 6,968
patients experienced AMI or died. The use of beta-blockers
was associated with reductions in mortality (HR=0.90; 95% con-
fidence limits [CL]: 0.84 - 0.96) and death or AMI (HR=0.92;
CL: 0.87 to 0.97). However, although the referenced study was
recently published, the authors did not include information
regarding the rates of PCI or in-hospital outcomes. Therefore, it
was difficult to compare these findings with our results (14).
In another retrospective cohort study, the use of beta-
blockers in 179 patients who experienced prehospital cardiac
arrest was measured. The odds ratio for beta-blocker use
among patients with cardiac arrest presenting as pulseless
electrical activity versus ventricular fibrillation was 3.7
(95% CI 1.9—7.2), which indicates that a relationship exists
between beta-blocker use and arrest rhythms (15). These
findings were related to results from other trials showing a
reduction in sustained ventricular arrhythmias with beta-
blocker use after AMI and are in agreement with our results
(7,8,16,17). Although the differences identified in our study
were not significant, potentially due to the low number of
included patients, there was a clear trend correlating the use
of beta-blockers with a reduction in sustained ventricular
arrhythmia. The most interesting finding is that the benefit of
beta-blocker use was not associated with long-term prog-
nosis, as has been reported in many previous studies, but
rather with in-hospital outcomes starting within 24 hours of
admission. We also observed a clear trend towards a reduc-
tion in sustained ventricular arrhythmia with beta-blocker
use, although the relationship was not significant.
In 2005, the COMMIT trial was published. This study in-
cluded 45,852 patients treated within 24 hours of AMI (93%
had STEMI or bundle branch block) who were randomized
into intravenous metoprolol and placebo groups. Among the
patients in the metoprolol group, approximately 9.4% experi-
enced at least one event compared with 9.9% of the patients
in the placebo group (p=0.1). The use of metoprolol was rela-
ted to lower rates of reinfarction (2.0% vs 2.5%; p=0.001) and
ventricular fibrillation (2.5% vs 3.0%; p=0.001). However, the
incidence of cardiogenic shock was higher in the metoprolol
group (5.0% vs 3.9%; po0.00001). Considering these results,
intravenous beta-blocker use should be delayed until the
hemodynamic condition after AMI has stabilized. Although
the results in the referenced study argued against the use of
beta-blockers in AMI, the overall conclusion that adequate use
of oral beta-blockers within the first 24 hours of admission
is beneficial is similar to our own findings, although caution
should be exercised regarding any contra-indications. Overall,
we found that clinical benefits were associated with the above
approach (9).
Another recent study investigated the effects of beta-
blockers in patients with STEMI in the PCI era. During a
follow-up period of approximately 48 months, mortality did
not differ between patients with and without beta-blocker
use (5.2% vs 6.2%, p=0.786). However, in patients with a high
ischemic risk (defined by the GRACE risk score), beta-
blocker treatment was associated with a significantly lower
mortality. Inconsistent with the COMMIT trial, the refer-
enced study did not indicate that beta-blocker use was
associated with worse results in any outcome. However, the
authors proposed the individualization of treatment, com-
menting that the implementation of beta-blocker therapy in
the PCI era for discharged patients may need to be assessed
based on the individual mortality risk (18).
Table 2 - Multivariate analysis of in-hospital outcomes for patients with or without the use of beta-blockers within the first 24 hours of
admission.
Beta-blocker + Beta-blocker - OR CI (95%) p
Reinfarction 1.0% 0.9% 0.83 0.62 – 4.67 0.9
Cardiogenic shock 3.5% 9.4% 0.57 0.29 – 1.12 0.1
Bleeding 2.3% 6.0% 1.28 0.57 – 2.90 0.55
SVA 0.7% 3.8% 1.24 0.82 – 2.56 0.23
Stroke 0.8% 0.3% 0.81 0.14 – 8.42 0.9
Mortality 2.7% 9.1% 8.12 1.53 – 14.56 0.02
MACE 11% 29.5% 4.55 2.05 – 10.09 0.032
Legend: CI=confidence interval; SVA=sustained ventricular arrhythmia; MACE=major adverse cardiac events.
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Due to the debate over the use of beta-blockers for ACS in
the reperfusion era, a review of randomized trials evaluating
beta-blocker treatment of AMI was undertaken. The primary
outcome was all-cause mortality, and trials were divided into
reperfusion era or pre-reperfusion era. Approximately 102,003
patients were included. It was found that beta-blockers signi-
ficantly reduced mortality (p=0.02) in the pre-reperfusion era,
but not in the reperfusion era. The incidences of AMI and
angina were reduced in both groups. However, in the reper-
fusion era, increases in the incidences of heart failure and
cardiogenic shock were related to the use of beta-blockers.
Based on these findings, the authors proposed that guidelines
should reconsider the strength of recommendations for beta-
blockers post AMI. It is important to note that the main results
obtained in the reperfusion era have been gathered by the
COMMIT trial. However, in a sensitivity analysis that exclu-
ded this trial, there was still no benefit of beta-blockers
regarding mortality in the reperfusion era. The categorization
of pre-reperfusion vs reperfusion era was not performed based
on calendar years, as there was wide variability in the use of
medication and reperfusion. In addition, the referenced study
considered both oral and intravenous beta-blockers (3).
Our results indicate that the use of beta-blockers within the
first 24 hours after ACS in the reperfusion era could decrease
in-hospital mortality and MACE. Important factors related to
this relationship were identified, such as the exclusion of
intravenous beta-blockers and the inclusion of both STEMI
and NSTEMI. Additionally, the reduced in-hospital mortality
identified in the present work has not been widely reported
in the literature, possibly because most previous studies have
focused on a long-term follow-up period.
Limitations
This study had some limitations. For example, the design
was observational, and only a small number of patients were
included. Additionally, many of the baseline characteristics
of the patients with and without beta-blockers were different.
Furthermore, we did not separate the analysis according to
type of beta-blocker used. All medications used in patients
with coronary disease were administered according to the
preferences of the physician. The rationale behind which
medications were administered was not described.
In patients with acute coronary syndrome who undergo
early intervention, the use of oral beta-blockers within the first
24 hours of symptom onset reduced in-hospital mortality and
the incidence of MACE without increasing the incidences of
cardiogenic shock and sustained ventricular arrhythmia.
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